| Primary Peritoneal Carcinoma studied in …STUDIED_INderived10 of 294show all (up to 200) |
|---|
| → studied in | NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 294 trials mapped (97 active) | — | — | Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 294 trials mapped (97 active) | — | — | Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped CURATED_BROADER · 294 trials mapped (97 active) | — | — | Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 294 trials mapped (97 active) | — | — | Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 294 trials mapped (97 active) | — | — | Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07708753Phase 3 · recruiting A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 294 trials mapped (97 active) | — | — | Platinum-Resistant Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 294 trials mapped (97 active) | — | — | Primary Peritoneal Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05446298Phase 2 · active not recruiting ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 294 trials mapped (97 active) | — | — | Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 294 trials mapped (97 active) | — | — | Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07495124Phase 2 · recruiting IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence · condition mapped ONTOLOGY_EXACT · 294 trials mapped (97 active) | — | — | Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |